Abstract

Human induced pluripotent stem cells (hIPSCs) have initiated a higher degree of successes in disease modelling, preclinical evaluation of drug therapy and pharmaco-toxicological testing. Since the discovery of iPSCs in 2006, many advanced techniques have been introduced to differentiate iPSCs to cardiomyocytes, which have been progressively improved. The disease models from iPSC-induced cardiomyocytes (iPSC-CM) have been successfully helping to study a variety of cardiac diseases such as long QT syndrome, drug-induced long QT, different cardiomyopathies related to mutations in mitochondria or desmosomal proteins and other rare genetic diseases. IPSC-CMs have also been used to screen the role of chemicals in cardiovascular drug discovery and individualisation of drug dosages. In this review, the quality of current procedures for characterisation and maturation of iPSC-CM lines will be discussed. Also, we will focus on time efficiency and cost of standard differentiation methods after reprogramming.

摘要

人类诱导多能干细胞 (hIPSC) 在疾病建模、药物治疗的临床前评估和药理学测试方面取得了更高程度的成功。自 2006 年发现 iPSCs 以来，许多先进的技术被引入以将 iPSCs 分化为心肌细胞，并得到逐步改进。iPSC 诱导的心肌细胞 (iPSC-CM) 的疾病模型已成功地帮助研究多种心脏病，例如长 QT 综合征、药物诱导的长 QT、与线粒体或桥粒蛋白突变相关的不同心肌病以及其他罕见遗传病疾病。IPSC-CM 还被用于筛选化学物质在心血管药物发现和药物剂量个体化中的作用。在这篇评论中，将讨论当前 iPSC-CM 线的表征和成熟程序的质量。此外，我们将关注重新编程后标准微分方法的时间效率和成本。